Drug Trial News

RSS

ETC-1002 drug reduces LDL cholesterol levels in hypercholesterolemic patients

Early data suggest ETC-1002, a drug that regulates lipid and carbohydrate metabolism, had a significant impact on cholesterol levels and improved factors believed to contribute to cardio-metabolic diseases, say researchers from the Methodist DeBakey Heart & Vascular Center, the Baylor College of Medicine, and Esperion Therapeutics, Inc., who are presenting their work at the 2012 American College of Cardiology Scientific Session in Chicago.

26 Mar 2012

Enrollment complete in Clovis' CO-101 pivotal study for metastatic pancreatic cancer

Clovis Oncology, Inc. announced today that it has reached the target enrollment in its pivotal LEAP (Low hENT1 and Adenocarcinoma of the Pancreas) study of CO-101 in metastatic pancreatic cancer.

26 Mar 2012

Mutational profiling could determine which AML patients will benefit from dose-intensive chemotherapy

An international group of researchers, including those from Moffitt Cancer Center in Tampa, Fla., have published a paper in the March 14 issue of the New England Journal of Medicine reviewing the results of a study that analyzed mutations in 18 genes of 398 patients who had acute myeloid leukemia.

26 Mar 2012

Positive results from Amgen's AMG 145 Phase 1b study on patients with LDL-C

Amgen announced today positive results from a Phase 1b clinical study of AMG 145, an investigational PCSK9 inhibitor, in patients with high cholesterol who were taking statins. The study demonstrated that multiple doses of AMG 145 significantly reduced serum low density lipoprotein cholesterol (LDL-C), also known as "bad" cholesterol, by up to 81 percent versus placebo (maximum reduction) in subjects on low to moderate doses of statins/

26 Mar 2012

New IVIG trial can reduce OCD symptoms in children with PANDAS

Criteria for a broadened syndrome of acute onset obsessive compulsive disorder (OCD) have been proposed by a National Institutes of Health scientist and her colleagues. The syndrome, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), includes children and teens that suddenly develop on-again/off-again OCD symptoms or abnormal eating behaviors, along with other psychiatric symptoms - without any known cause.

26 Mar 2012

GenVec announces data from respiratory syncytial virus vaccine program

GenVec, Inc. (Nasdaq: GNVC) announced today that data were presented on GenVec's respiratory syncytial virus (RSV) vaccine program at the "Keystone Symposium on Viral Immunity and Host Gene Influence", which is taking place in Keystone, Colorado from March 21-26, 2012.

26 Mar 2012

New cholesterol lowering drugs on the horizon

The new drugs in development by pharmaceutical makers are injectable medications that block a protein called PCSK9. These drugs have shown promise in early clinical trials for slashing bad LDL cholesterol further than widely used statins can alone. Their biggest advocates say PCSK9 blockers have the potential to be the next multibillion-dollar class of heart drugs.

25 Mar 2012

Combination of everolimus and exemestane reduces spread of cancer in the bone

Results from a phase III clinical trial evaluating a new treatment for breast cancer in post-menopausal women show that the combination of two cancer drugs, everolimus and exemestane, significantly improves bone strength and reduces the chances of cancer spreading (metastasising) in the bone.

23 Mar 2012

China SFDA approves Taibang's clinical trials for human fibrinogen

China Biologic Products, Inc., one of the leading plasma-based biopharmaceutical companies in the People's Republic of China, today announced that its indirectly owned subsidiary, Shandong Taibang Biological Products Co., Ltd., recently received approval from the China State Food and Drug Administration to begin clinical trials for its human fibrinogen to be used to treat congenital fibrinogen deficiency and acquired fibrinogen deficiency.

23 Mar 2012

Emergent receives NIAID grant to advance development of MVA85A TB vaccine

Emergent BioSolutions Inc. today announced that it has received a multi-year grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to advance the development of MVA85A, a candidate vaccine against tuberculosis.

23 Mar 2012

Working together to fight TB

In this post in USAID's "IMPACTblog," guest blogger Joanna Breitstein, director of communications for the TB Alliance, describes an event organized by the Critical Paths to TB Drug Regimens that took place on Monday, "heralding the launch of a new clinical trial that tests tuberculosis drugs in combination."

22 Mar 2012

CINJ clinical trials leader receives 2012 Award of Excellence from HOPA

Susan Goodin, PharmD, FCCP, BCOP, associate director of clinical trials and therapeutics at The Cancer Institute of New Jersey (CINJ) has received the 2012 Award of Excellence from the Hematology/Oncology Pharmacy Association.

22 Mar 2012

Antidepressants can play a key role in relieving pain associated with OA

Antidepressants can play a key role in alleviating painful conditions like osteoarthritis and may result in fewer side effects than traditionally prescribed drug regimes, such as anti-inflammatories and opioids, according to a perspective paper published online ahead of print publication by the International Journal of Clinical Practice.

22 Mar 2012

Researchers unveil 'blueprint' to guide next steps in TB vaccine development

"On Tuesday, a global alliance of researchers and scientists -- led by the Stop TB Partnership, an umbrella group of health groups -- unveiled a 'blueprint' to develop a new vaccine against tuberculosis (TB) that aims to disrupt transmission in hard-hit countries and communities," the Wall Street Journal reports.

22 Mar 2012

International study into safety of NSAIDs reaches enrollment milestone

An international study into the safety of some of the most widely used medicines has reached a significant milestone by recruiting its 6,000th patient.

22 Mar 2012

BHR Pharma enrolls first 400 patients for BHR-100 pivotal trial for TBI

As communities in the United States gather in support of Traumatic Brain Injury (TBI) Awareness Day, BHR Pharma, LLC's SyNAPSe- clinical trial reaches an important enrollment milestone.

22 Mar 2012

TACT believes that Halo's HT-100 may effectively treat DMD

Halo Therapeutics, LLC, a clinical-stage biopharmaceutical company developing novel therapeutics for rare fibrotic diseases, announced today that the TREAT-NMD Advisory Committee on Therapeutics (TACT) has reviewed HT-100, Halo's drug candidate for Duchenne muscular dystrophy (DMD), and believes the compound has potential based on the proposed mechanism.

21 Mar 2012

TB Alliance launches Phase II clinical trial to test new drug regimen among people with TB, MDR-TB

The TB Alliance on Monday announced it has launched a Phase II clinical trial "of a new treatment regimen for tuberculosis, including for patients with resistance to existing multi-drug programs," Agence France-Presse reports.

21 Mar 2012

DIAN-TTU to receive $4.2M Alzheimer's Association research grant

The Alzheimer's Association announced today the awarding of its largest ever research grant – nearly $4.2 million dollars over four years – to the Dominantly Inherited Alzheimer's Network–Therapeutic Trials Unit (DIAN-TTU), based at Washington University School of Medicine in St. Louis, to enable the program to move forward more quickly with innovative drug and biomarker trials in people with genetically-based, young-onset Alzheimer's disease.

21 Mar 2012

Alzheimer's Association awards $4.2M grant to DIAN-Therapeutic Trials Unit

Washington University School of Medicine in St. Louis has received nearly $4.2 million from the Alzheimer's Association to accelerate the launch of the first clinical trials to prevent the symptoms of Alzheimer's disease.

21 Mar 2012